Yongsheng Wang

发表

Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma

S. Ren, Caicun Zhou, Jiayu Li, 2012, Cell Biochemistry and Biophysics.

HIF-1-dependent heme synthesis promotes gemcitabine resistance in human non-small cell lung cancers via enhanced ABCB6 expression

J. Lan, B. Shao, Shuang Wu, 2021, Cellular and Molecular Life Sciences.

Emerging Role of Long Non-Coding RNAs in Non-Small Cell Lung Cancer:Progress and Prospects

Jieqing Zhao, Weijun Wu, Yongsheng Wang, 2017 .

Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma

S. Ren, Caicun Zhou, Jiayu Li, 2012, Cell Biochemistry and Biophysics.

MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.

H. Xia, Caicun Zhou, Songwen Zhou, 2012, Asian Pacific journal of cancer prevention : APJCP.

MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.

S. Ren, Caicun Zhou, Songwen Zhou, 2014, Lung cancer.

EBUS-TBNA Provides Highest RNA Yield for Multiple Biomarker Testing from Routinely Obtained Small Biopsies in Non-Small Cell Lung Cancer Patients - A Comparative Study of Three Different Minimal Invasive Sampling Methods

T. Henzler, S. Ren, Caicun Zhou, 2013, PloS one.

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians

Caicun Zhou, G. Schmid‐Bindert, Caicun Zhou, 2012, Therapeutic advances in medical oncology.

Efficacy of third‐generation chemotherapeutic agents combined with cisplatin or carboplatin in 3100 Chinese patients with advanced non‐small‐cell lung cancer

S. Ren, Caicun Zhou, G. Schmid‐Bindert, 2013, Thoracic Cancer.

Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never‐smoker women with pulmonary adenocarcinoma

S. Ren, Caicun Zhou, G. Schmid‐Bindert, 2012, Cancer.

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

Ying Cheng, Jian-hua Chang, Yunpeng Liu, 2020, The Lancet. Respiratory medicine.

Serum cytokine levels in patients with advanced non‐small cell lung cancer: correlation with clinical outcome of erlotinib treatment

S. Ren, Caicun Zhou, G. Schmid‐Bindert, 2013, Chinese medical journal.

Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines.

Daoyuan Wang, Caicun Zhou, Songwen Zhou, 2013, Cancer biotherapy & radiopharmaceuticals.

Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer

Qinghua Xu, Caicun Zhou, S. Meng, 2015, Thoracic cancer.

Individualized chemotherapy in advanced NSCLC patients based on mRNA levels of BRCA1 and RRM1

S. Ren, Caicun Zhou, Songwen Zhou, 2012, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.

Bing Li, S. Ren, Caicun Zhou, 2012, Lung cancer.

The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC).

Yunpeng Liu, N. Yang, M. Tao, 2022, Journal of Clinical Oncology.

Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced solid tumors.

Yunpeng Liu, L. Shen, J. Gong, 2021 .

Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with ROS1 fusion: Preliminary results of TRUST.

N. Yang, M. Tao, Caicun Zhou, 2021 .

Extended resection of the left atrium, great vessels, or both for locally advanced lung cancer: An experience of 248 cases

Jin-Ji Yang, Qinghua Zhou, Zhenfan Yang, 2000 .